Position of the Transparency Council – Qalsody (tofersen)
At its meeting on 12 May 2025, the Transparency Council adopted position No. 56/2025 on the appraisal of drug Qalsody (tofersen) under the drug program “Treatment of patients with amyotrophic lateral sclerosis (ICD 10: G12.2)”